No registrations found.
ID
Source
Health condition
Cystic fibrosis
Sponsors and support
Intervention
Outcome measures
Primary outcome
Plasma tobramycine levels within the target range
Secondary outcome
Influence of different parameter like e.g. weight, kidney function, male/female on the dosage.
Background summary
Patients with cystic fibroses often receive the antibiotic tobramycin during a long period to treat Pseudomonas aeruginosa infection. During standard care tobramycin levels in blood are determined to give an indication of safety and efficacy. When the tobramycin levels are outside a certain range, the dosage will be adjusted. In this study we will retrospectively determine if adjustment of the dosage was effective and if there are certain factors influencing the dosage (e.g. body weight).
Study objective
Therapeutic drug monitoring is effective in optimizing treatment with tobramycin and reduces side effects.
Study design
Tobramycine levels of 2011, 2012 and 2013 will be retrospectively analysed in 2014
Intervention
No interventions: retrospective, observational study
Meibergdreef 9
E.M. Kemper
Amsterdam 1105 AZ
The Netherlands
020-5667955
e.m.kemper@amc.nl
Meibergdreef 9
E.M. Kemper
Amsterdam 1105 AZ
The Netherlands
020-5667955
e.m.kemper@amc.nl
Inclusion criteria
- Patients with cystic fibroses.
- Treatment with tobramycin
- Plasma concentration of tobramycine routinely measured
Exclusion criteria
None
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4420 |
| NTR-old | NTR4544 |
| Other | Kemper : E.M. |